8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Mar 16, 2016)

Filed March 16, 2016For Securities:ELV

Summary

Elevance Health, Inc. (then Anthem, Inc.) filed an 8-K on March 16, 2016, primarily to reaffirm its financial guidance for the full year 2016. The company communicated to securities analysts and investors that it expected net income to be greater than $10.35 per share, with over $0.45 per share attributed to the amortization of other intangible assets. Excluding this specific item, the company maintained its outlook for adjusted net income to exceed $10.80 per share. This guidance explicitly excluded potential transaction costs related to the pending acquisition of Cigna Corporation, any investment gains or losses, and other-than-temporary impairment losses on investments. These exclusions are consistent with the company's methodology for calculating adjusted net income, providing clarity on the underlying operational performance expected. The filing also included standard forward-looking statement disclaimers, highlighting various risks and uncertainties that could affect future results, including those related to the Cigna acquisition and regulatory environments.

Key Highlights

  • 1Reaffirmed 2016 full-year net income guidance of greater than $10.35 per share.
  • 2Projected adjusted net income for 2016 to be greater than $10.80 per share, excluding specific items.
  • 3Guidance excludes transaction costs associated with the Cigna acquisition.
  • 4Guidance excludes investment gains/losses and other-than-temporary impairment losses.
  • 5Disclosure made during meetings with securities analysts and investors between March 16 and March 31, 2016.
  • 6Included standard forward-looking statement disclaimers and risk factors.

Frequently Asked Questions

The primary purpose of this 8-K filing is to reaffirm Elevance Health's (then Anthem, Inc.) financial guidance for the full year 2016 to securities analysts and investors. It clarifies the company's expected net income and adjusted net income per share for the year.

The adjusted net income guidance excludes transaction costs related to the acquisition of Cigna Corporation, any investment gains or losses, and any other-than-temporary impairment losses on investments.

The guidance was provided to securities analysts and investors during meetings held between March 16, 2016, and March 31, 2016.

No, the guidance explicitly states that it does not include any transaction costs associated with the acquisition of Cigna Corporation. This suggests the guidance reflects the company's standalone operational performance expectations for 2016, separate from the anticipated acquisition expenses.